REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel hydroxyl dendrimer therapeutics...
Round Comprised of New and Former Investors, Including Dr. Josef Ackermann, Wilhelm Beier, Toni Kroos, and Carsten Maschmeyer First of...
Pre-clinical trial demonstrates ability of nVNS to decrease amount of brain injury, decrease anxiety and improve motor function post injuryROCKAWAY,...
AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared...
SAN FRANCISCO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein...
Exclusive license from Helmholtz Munich will enable ITM to access IP and know-how to develop and commercialize ITM-31 for glioblastoma...
SinaptiStim™ – AD System provides personalized and precision-delivered electromagnetic therapeutic approach to treating cognitive and functional decline in Alzheimer’s disease...
BOSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering...
CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of...
Topline Data Expected December 2022CARSON CITY, Nev., Oct. 19, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the...
BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS)...
Phase 1 Study Will Include Biomarker Selected Patients with Advanced Solid TumorsWILMINGTON, Del., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Prelude...
VANCOUVER, British Columbia, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:...
Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven’s portfolio of precision oncology programsCombined company is expected to...
- Robust post-dosing changes continue to be seen in key markers associated with severity of disease - Pharmacodynamic data from...
Alzheimer’s Patients Who Complete Participation in a Phase 3 Study of Simufilam are Eligible to Enroll52-week Study of Simufilam 100...
Higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baselineLack of activity compared to 0.3 mg...
Company Spotlights its Appreciation to Physical Therapists Trained in its Innovative PoNS Therapy™ in Honor of National Physical Therapy MonthNEWTOWN,...
PHILADELPHIA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative...
Company expects to commence patient enrollment and dosing in Q1 2023OCALA, Fla, Oct. 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech...